Celularity(CELUW)

View 6 open jobs Website LinkedIn Careers Page

Focus: Celularity is a public biotechnology company specializing in placenta-derived stem cell therapies, with a diversified pipeline spanning oncology, immunology, and regenerative medicine. The company is early-stage in clinical development with 14 active trials and modest revenue generation ($54M in FY2025).

Cell Therapy

Profile data last refreshed 2h ago · AI intelligence enriched 2mo ago

Funding Stage

PUBLIC

Open Jobs

6-1 this month

Stable — net -1 jobs in 30d

3 added, 4 removed. Backfill posture.

Should You Work at Celularity?

AI assessment

Celularity offers early-stage biotech upside in a novel modality, but acute cash depletion and clinical pipeline immaturity present significant execution risk; best suited for risk-tolerant early-career scientists seeking deep technical ownership, not stability-seeking professionals.

Why Work Here

Pioneering proprietary technology platform (placenta-derived stem cells) with potential first-mover advantage in multiple therapeutic areas not yet saturated by traditional biologics.

Data completeness

5/9 — Partial

Company HealthStrong

Pipeline

Early-stage

17 total

LOE Risk

Protected

No near-term cliffs

Hiring

Stable

Revenue

$54M

Pipeline & Clinical Trials

PDA001

Crohns Disease

PHASE_1

Clinical Trials (1)

NCT01769755A Randomized, Double-Blind, Placebo-Controlled Dose-Escalation Study to Determine the Safety and Efficacy of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Crohn's Disease

Phase 1

Help build intelligence for Celularity

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Public company status (NASDAQ: CELU) with demonstrated revenue growth (135% YoY from FY2024 to FY2025) and recent C-suite expansion (new Chief Commercial Officer appointed June 2026), signaling growth-phase momentum.

Diverse pipeline across 17 indications offers broad exposure to oncology, inflammation, and regenerative medicine—valuable experience for career mobility across multiple specialties.

Watch Out For

Severe cash constraint: only $738K on hand as of FY2025 despite $57.9M net loss, creating immediate refinancing risk and potential restructuring pressure within 6-12 months.
No Phase 3 programs and only 6 Phase 2 programs across 17 indications suggests high attrition risk and extended timeline to revenue inflection; minimal near-term clinical catalysts.
Only 3 active job openings (Finance ×2, QA ×1) indicates minimal hiring momentum despite public-stage status, limiting internal career progression opportunities.
Regulatory pathway accelerated by Florida law (June 2026) may create compliance complexity and potential FDA confrontation over off-label commercialization practices.

Generated by Claude from Celularity's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

PNK-007

Leukemia, Myeloid, Acute

PHASE_1

Clinical Trials (1)

NCT02781467A Safety Study of Human Cord Blood Derived, Culture Expanded Natural Killer Cell (PNK-007) Infusion With Subcutaneous Recombinant Human IL-2 (rhIL-2) in Adults With Relapsed and/or Refractory Acute Myeloid Leukemia (AML)

Phase 1

CYNK-001

Multiple Myeloma

PHASE_1

Clinical Trials (1)

NCT04309084Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma

Phase 1

PDA001

Stage 2 Pulmonary Sarcoidosis

PHASE_1

Clinical Trials (1)

NCT01440192Safety of Intravenous Infusion of Human Placenta-Derived Cells (PDA001) for the Treatment of Adults With Stage II or III Pulmonary Sarcoidosis

Phase 1

CYNK001-IV

Astrocytoma, Grade IV

PHASE_1

Clinical Trials (1)

NCT04489420Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM

Phase 1

CYNK-001

Leukemia

PHASE_1

Clinical Trials (1)

NCT04310592Natural Killer Cell (CYNK-001) Infusions in Adults with AML

Phase 1

rhIL-2

Multiple Myeloma

PHASE_1

Clinical Trials (1)

NCT02955550A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)

Phase 1

3 x 10^6 cells

Peripheral Arterial Disease

PHASE_1

Clinical Trials (1)

NCT01859117Study of PDA-002 in Subjects With Peripheral Arterial Disease and Diabetic Foot Ulcers

Phase 1

CYNK-101

Metastatic HER2 Positive Gastroesophageal Junction Cancer

PHASE_1_2

Clinical Trials (1)

NCT05207722CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

Phase 1/2

CYNK-001

Coronavirus

PHASE_1_2

Clinical Trials (1)

NCT04365101Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19

Phase 1/2

CYNK-001 systemic and Intra cavity administration

Astrocytoma, Grade IV

PHASE_1_2

Clinical Trials (1)

NCT05218408CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type

Phase 1/2

Human Placenta-Derived Cells PDA001 Intravenous Infusion

Crohn's Disease

PHASE_2

PDA-002

Diabetic Foot

PHASE_2

Clinical Trials (1)

NCT02460081Hemodynamic Effects of Intramuscular PDA-002 in Subjects Who Have Diabetic Foot Ulcer With Peripheral Arterial Disease

Phase 2

3 x 10^6 cells

Peripheral Arterial Disease

PHASE_2

Clinical Trials (1)

NCT02264288Efficacy and Safety of Intramuscular PDA-002 in Subjects With Diabetic Foot Ulcer With and Without PAD.

Phase 2

PDA-002

Diabetic Nephropathies

PHASE_2

Clinical Trials (1)

NCT02552277A Efficacy and Safety Study of Intramuscular Injection of Human Placenta-Derived Cells (PDA-002) in Subjects With Diabetic Peripheral Neuropathy

Phase 2

PDA001

Rheumatoid Arthritis

PHASE_2

Human Placenta-Derived Cells PDA001-

Stroke, Acute

PHASE_2